ライフサイエンスコーパス: major histocompatibility complex

1 ope overlapped with the binding site for the major histocompatibility complex.

2 n of Parkinson's disease with alleles of the major histocompatibility complex.

3 ion of random self-peptides presented on the major histocompatibility complex.

4 ily target peptide antigens presented by the major histocompatibility complex.

5 compatibility complex-1 tail, and subsequent major histocompatibility complex-1 downregulation and im

6 the mu1 subunit of adaptor protein 1 and the major histocompatibility complex-1 tail, and subsequent

7 ciation of Parkinson's disease with specific major histocompatibility complex alleles.

8 ne responses by downregulating expression of major histocompatibility complex and interfering with an

9 n of the transmembrane complexes between the major histocompatibility complex and the T cell receptor

10 However, the mechanisms by which major histocompatibility complex-associated genetic susc

11 is performant, flexible and supports several major histocompatibility complex binding affinity predic

12 ning for antigen-reactive TCRs using peptide major histocompatibility complex binding and cellular ac

13 lerosis genetics, we performed genotyping of major histocompatibility complex-borne microsatellites a

14 he variable nature of this protein, a common major histocompatibility complex class (MHC-II) epitope

15 M subtypes for their ability to downregulate major histocompatibility complex class A (MHC-A) and MHC

16 the repertoire of peptides presented by the major histocompatibility complex class I (MHC I) is a ke

17 Adaptive immunity vitally depends on major histocompatibility complex class I (MHC I) molecul

18 in different steps during the maturation of major histocompatibility complex class I (MHC I) protein

19 es presented by the evolutionarily conserved major histocompatibility complex class I (MHC I)-related

20 50% of rhesus macaques (RMs) expressing the major histocompatibility complex class I (MHC-I) allele

21 To understand the role of major histocompatibility complex class I (MHC-I) and MHC

22 cently identified specific transactivator of major histocompatibility complex class I (MHC-I) compone

23 Interestingly, CXCL14 expression restores major histocompatibility complex class I (MHC-I) express

24 The NLR family member NLRC5 regulates major histocompatibility complex class I (MHC-I) express

25 Second, polymorphism of the human major histocompatibility complex class I (MHC-I) gene re

26 iment expressed the elite control-associated major histocompatibility complex class I (MHC-I) molecul

27 efficiently presented in the context of the major histocompatibility complex class I (MHC-I) molecul

28 Tumors frequently subvert major histocompatibility complex class I (MHC-I) peptide

29 c CD8(+) T cell responses were documented by major histocompatibility complex class I (MHC-I) tetrame

30 inst NS5 were also elicited, as evidenced by major histocompatibility complex class I (MHC-I) tetrame

31 y mutations or loss of heterozygosity of the major histocompatibility complex class I (MHC-I), which

32 are needed to identify peptides presented by major histocompatibility complex class I (MHC-I).

33 ature antigenic peptides for presentation by major histocompatibility complex class I (MHCI) molecule

34 iated immunity is the recognition of peptide-major histocompatibility complex class I (p-MHC I) prote

35 Peptide-loaded major histocompatibility complex class I (pMHC-I) molecu

36 ific CD8(+) T cells, applying peptide-loaded major histocompatibility complex class I (pMHCI) tetrame

37 tained the ability to induce upregulation of major histocompatibility complex class I antigen express

38 he cytosol, where they access the endogenous major histocompatibility complex class I antigen process

39 neurons by preventing their up-regulation of major histocompatibility complex class I antigen, thus p

40 Major histocompatibility complex class I chain-related (

41 8 T cells targeting dominant and subdominant major histocompatibility complex class I epitopes prolif

42 dition, sorafenib was found to down-regulate major histocompatibility complex class I expression of t

43 ways and frequent B2M alterations that limit major histocompatibility complex class I expression, as

44 Major histocompatibility complex class I molecules (MHC

45 this study, we evaluated the contribution of major histocompatibility complex class I molecules to br

46 tumours that have lost surface expression of major histocompatibility complex class I molecules.

47 ncorporating proximal variant correction for major histocompatibility complex class I neoantigen pept

48 ctural analysis shows FcRn is a nonclassical major histocompatibility complex Class I receptor, which

49 ons between SNPs and VL were observed in the major histocompatibility complex class I region (MHC I),

50 albumin, as well as a viral peptide-specific major histocompatibility complex class I tetramer, we in

51 eptide-MHC-I complex (where MHC-I represents major histocompatibility complex class I).

52 nodes (LNs), but not in the spleen, through major histocompatibility complex class I-dependent inter

53 between the hyperactive ERBB-STAT3 axis and major histocompatibility complex class I-mediated tumor

54 epitopes (amino acids 11-30 and 41-60) and 1 major histocompatibility complex class I-restricted epit

55 eract with peptides bound to the polymorphic major histocompatibility complex class Ia (MHC-Ia) and c

56 ine H2-O) is a highly conserved nonclassical major histocompatibility complex class II (MHC II) acces

57 enting antigenic peptides to CD4(+) T cells, major histocompatibility complex class II (MHC II) also

58 The major histocompatibility complex class II (MHC II)-CD4 i

59 aled alterations in both the CD11c(+) DC and major histocompatibility complex class II (MHC)-II(+) ma

60 AG-3) is an immune inhibitory receptor, with major histocompatibility complex class II (MHC-II) as a

61 genome-wide CRISPR-Cas9 screening, that the major histocompatibility complex class II (MHC-II) human

62 Major histocompatibility complex class II (MHC-II) molec

63 f-peptides displayed by a defined autoimmune major histocompatibility complex class II (MHC-II) molec

64 ncodes the beta subunit of the non-classical major histocompatibility complex class II (MHC-II)-like

65 ologous antigen-specific CD4(+) T cells in a major histocompatibility complex class II (MHC-II; HLA-D

66 A polymorphism at beta57 in some major histocompatibility complex class II (MHCII) allele

67 -DM (HLA-DM) is an integral component of the major histocompatibility complex class II (MHCII) antige

68 ia and that presentation of such antigens on major histocompatibility complex class II (MHCII) leads

69 erantigens to T cell receptors (TCRs) and/or major histocompatibility complex class II (MHCII) molecu

70 ate in DC-to-MC molecule transfers including major histocompatibility complex class II (MHCII) protei

71 cell effector responses during infection was major histocompatibility complex class II (MHCII)-depend

72 emoval of the complex of cognate peptide and major histocompatibility complex class II (pMHCII) from

73 Accessory molecules (major histocompatibility complex class II [MHC-II], CD80

74 ore, antibiotic-induced broad suppression of major histocompatibility complex class II antigen presen

75 UW-3/Cx) to induce infertility in mice whose major histocompatibility complex class II antigen was re

76 nduced deaminase, and immune evasion through major histocompatibility complex class II downregulation

77 nes in peripheral T-cell counts, and reduced major histocompatibility complex class II expression lev

78 pleen's weight, a lymphopenia, a decrease of major histocompatibility complex class II expression on

79 targeting class II transactivator attenuates major histocompatibility complex class II expression on

80 ased CD4 T-cell counts and downregulation of major histocompatibility complex class II expression on

81 also downregulation of the FCER2, CD52, and major histocompatibility complex class II genes.

82 We used major histocompatibility complex class II mismatched C57

83 teria, had stronger myocardial expression of major histocompatibility complex class II molecule and e

84 esenting a high density of peptides bound to major histocompatibility complex class II molecules (pMH

85 In spleen, an increased expression of major histocompatibility complex class II molecules on d

86 degraded, and the peptides are presented on major histocompatibility complex class II molecules, the

87 s are bacterial superantigens, which bind to major histocompatibility complex class II on antigen-pre

88 oximately 30-50%) in expression of CD11b and major histocompatibility complex class II on both monocy

89 ctivate T-cell-dependent immune responses by major histocompatibility complex class II presentation.

90 Furthermore, silencing of major histocompatibility complex class II reduces alloge

91 HCV-specific CD4(+) T-cell populations using major histocompatibility complex class II tetramers in v

92 rmore, MIA microglia increased expression of major histocompatibility complex class II that was coupl

93 rovide the first demonstration that not only major histocompatibility complex class II, but also clas

94 The major histocompatibility complex class-I (MHC-I) peptide

95 469 located on 6p22.1, and covering lncRNAs (major histocompatibility complex, class I, A (HLA-A) and

96 poietin 2; myeloperoxidase; lactoperoxidase; major histocompatibility complex, class I, A; major hist

97 bility complex, class II, isotype DR beta I; major histocompatibility complex, class I, C; and major

98 histocompatibility complex, class I, C; and major histocompatibility complex, class II, isotype DQ b

99 ajor histocompatibility complex, class I, A; major histocompatibility complex, class II, isotype DR b

100 ed lesion expression of inflammatory markers major histocompatibility complex-class II and IL6, lesio

101 usly shown to be TAAs, their presentation on major histocompatibility complex classes I (MHC-I) and I

102 IL-6 leads to long-term (>75 d) survival of major histocompatibility complex-different skin allograf

103 Major histocompatibility complex E (MHC-E) is a highly c

104 cells in solid tumors, HRSCs frequently lack major histocompatibility complex expression, and the mec

105 llects and expertly curates sequences of the major histocompatibility complex from non-human species

106 /c) and highly (Balb/c in C57BL/6) stringent major histocompatibility complex fully mismatched mouse

107 is highly specific and dependent on the host major histocompatibility complex genotype.

108 The major histocompatibility complex haplotype represents th

109 ssemblies to provide 100 completely resolved major histocompatibility complex haplotypes and to resol

110 Those results revealed two major histocompatibility complex haplotypes associated w

111 erential localization of DCs specialized for major histocompatibility complex I (MHC I) and MHC II pr

112 ase 1 (ERAP1) and ERAP2 critically shape the major histocompatibility complex I (MHC I) immunopeptido

113 s and macrophages acquire memory specific to major histocompatibility complex I (MHC-I) antigens, and

114 monstrated to epigenetically reverse the low major histocompatibility complex I expression caused by

115 on by T cells owing to the downregulation of major histocompatibility complex I surface expression.

116 gulated, consequently resulting in increased major histocompatibility complex I surface expression.

117 Major histocompatibility complex II (MHC II) molecules a

118 hes phagosomal tubule formation, and impairs major histocompatibility complex II (MHC-II) presentatio

119 ed with circulating neutrophils, with higher major histocompatibility complex II (MHCII) expression,

120 polyclonal stimulation, and displayed lower major histocompatibility complex II expression by antige

121 -permitting H2s or disease-nonpermitting H2b major histocompatibility complex II haplotypes.

122 atherosclerosis, we used a novel tetramer of major histocompatibility complex II to track T cells rea

123 y T cell differentiation, prolonged monocyte major histocompatibility complex II upregulation and per

124 These results indicate that major histocompatibility complex II-associated susceptib

125 subsets, resident cardiac MHCII(LO)CCR2(-) (major histocompatibility complex II/C-C motif chemokine

126 e associated with expression of genes in the major histocompatibility complex, including C4A and C4B,

127 mmunotherapies fail to exploit their in situ major histocompatibility complex-independent tumoricidal

128 uM) comparable to many alphabeta TCR-peptide major histocompatibility complex interactions.

129 rogate peptides derived from a yeast peptide major histocompatibility complex library of some of the

130 Continuous contact with self-major histocompatibility complex ligands is essential fo

131 To elucidate major histocompatibility complex-linked systemic scleros

132 s, targeting the BRCA1 gene, the entire 4-Mb major histocompatibility complex locus and 18 well-chara

133 an informative clinically relevant RIC mouse major histocompatibility complex-matched alloHCT model b

134 We investigated a murine model of major histocompatibility complex-matched multiple minor

135 ion of primary Sjogren's syndrome (pSS) with Major Histocompatibility Complex (MHC) alleles is quinte

136 Variants in major histocompatibility complex (MHC) and in interferon

137 ptors (TCRs) recognize antigens presented by major histocompatibility complex (MHC) and MHC class I-l

138 e antigens bound to molecules encoded by the major histocompatibility complex (MHC) and presented on

139 likelihood of neoantigen presentation by the major histocompatibility complex (MHC) and subsequent re

140 Conformational changes of major histocompatibility complex (MHC) antigens have the

141 n of inhibitory NK cell receptors with their major histocompatibility complex (MHC) class I (or HLA c

142 rogates tumour antigen peptides presented by major histocompatibility complex (MHC) class I and class

143 d human iPSCs lose their immunogenicity when major histocompatibility complex (MHC) class I and II ge

144 ational prediction tools to identify LASV GP major histocompatibility complex (MHC) class I and II T-

145 s of anti-tumor cytolytic activity and lower major histocompatibility complex (MHC) class I gene expr

146 Genetic variability across the three major histocompatibility complex (MHC) class I genes (hu

147 Here we found a central role for major histocompatibility complex (MHC) class I in contro

148 gen class I (HLA-I) molecules are encoded by major histocompatibility complex (MHC) class I loci in h

149 coding a transcription factor that regulates major histocompatibility complex (MHC) class I molecule

150 s long, are presented at the cell surface by major histocompatibility complex (MHC) class I molecules

151 ification of peptides that were presented on major histocompatibility complex (MHC) class I molecules

152 Major Histocompatibility Complex (MHC) class I molecules

153 In SWATH-MS major histocompatibility complex (MHC) class I proteins

154 Peptide antigen presentation by major histocompatibility complex (MHC) class I proteins

155 In comparison to the families of major histocompatibility complex (MHC) class I, MHC clas

156 be presented on the cell surface as part of major histocompatibility complex (MHC) class I, suggesti

157 ously expressed across primary TCLs, whereas major histocompatibility complex (MHC) class I, which ca

158 Mapping studies with major histocompatibility complex (MHC) class I- and clas

159 We identified major histocompatibility complex (MHC) class I-binding e

160 Neonatal Fc-receptor (FcRn), the major histocompatibility complex (MHC) class I-like Fc-r

161 ll targeting of virus-infected cells and the major histocompatibility complex (MHC) class I-primed CD

162 ors of bacterial riboflavin presented by the major histocompatibility complex (MHC) class I-related m

163 ost current strategies use genes that encode major histocompatibility complex (MHC) class I-restricte

164 sponses by enhancing peptide presentation by major histocompatibility complex (MHC) class I.

165 e protein-derived antigens in the context of major histocompatibility complex (MHC) class Ia and clas

166 with pools of dengue virus-derived predicted major histocompatibility complex (MHC) class II binding

167 CD4 T cells and major histocompatibility complex (MHC) class II molecule

168 T cells, even in tumours that do not express major histocompatibility complex (MHC) class II molecule

169 produces antigenic peptides for loading onto major histocompatibility complex (MHC) class II molecule

170 TCR on differentiating CD4(+) T cells or of major histocompatibility complex (MHC) class II on intes

171 IECs constitutively express low levels of major histocompatibility complex (MHC) class II proteins

172 e furthermore find that a variant within the major histocompatibility complex (MHC) class II region c

173 Recently, major histocompatibility complex (MHC) class II tetramer

174 model of chronic typhoid fever combined with major histocompatibility complex (MHC) class II tetramer

175 resentation, including the gene encoding the major histocompatibility complex (MHC) class II transact

176 screen in human cells, we identify that the major histocompatibility complex (MHC) class II transact

177 We exemplify this concept with SIEC major histocompatibility complex (MHC) class II, which i

178 In a complementary approach, we generated major histocompatibility complex (MHC) class II-restrict

179 tation of antigen peptides in the context of major histocompatibility complex (MHC) class II.

180 Also, individuals with locally rare major histocompatibility complex (MHC) class IIb genotyp

181 The major histocompatibility complex (MHC) contains the most

182 y of antigenic peptides displayed in a given major histocompatibility complex (MHC) context.

183 en presenting cells (APCs) with intact donor major histocompatibility complex (MHC) derived from allo

184 ter bone marrow transplantation (BMT) across major histocompatibility complex (MHC) disparities and m

185 Major histocompatibility complex (MHC) genes encode prot

186 Proteins encoded by the classical major histocompatibility complex (MHC) genes incite the

187 h mismatches at half (haploidentical) or all major histocompatibility complex (MHC) genes.

188 a unique group of animals that have limited major histocompatibility complex (MHC) genetic diversity

189 ngest association with AD risk occurred with major histocompatibility complex (MHC) haplotype A*03:01

190 Although allelic diversity at the major histocompatibility complex (MHC) has implications

191 The major histocompatibility complex (MHC) has long served a

192 Generally, this approach is referred to as major histocompatibility complex (MHC) homo-to-hetero tr

193 st evidence for the role of an allele of the major histocompatibility complex (MHC) I gene HLA-B in t

194 ost antigenic peptides that bind stably to a major histocompatibility complex (MHC) I molecule for di

195 Disruption of the non-classical Major Histocompatibility Complex (MHC) Ib molecule Qa-1

196 can operate simultaneously by analysing the major histocompatibility complex (MHC) in guppies (Poeci

197 The major histocompatibility complex (MHC) is a central comp

198 The Major Histocompatibility Complex (MHC) is a key componen

199 The major histocompatibility complex (MHC) is responsible fo

200 The Major Histocompatibility Complex (MHC) is the most genet

201 strongest common genetic associations in the major histocompatibility complex (MHC) locus, an associa

202 a population level involves variation in the major histocompatibility complex (MHC) locus, but the ge

203 in and its feasibility in a clinical setting.Major histocompatibility complex (MHC) matching improves

204 er been described in the context of multiple major histocompatibility complex (MHC) mismatches.

205 Evidence is mounting that the major histocompatibility complex (MHC) molecule HLA-F (h

206 Nonclassical (class-Ib) major histocompatibility complex (MHC) molecules (MHC-Ib

207 Major histocompatibility complex (MHC) molecules are exp

208 sed congenic mice to examine the function of major histocompatibility complex (MHC) molecules in elim

209 -7 (HHV-7) U21 glycoprotein binds to class I major histocompatibility complex (MHC) molecules in the

210 alphabeta T cell receptor (TCR) with peptide-major histocompatibility complex (MHC) molecules on anti

211 to target cells that present cognate peptide-major histocompatibility complex (MHC) molecules.

212 or endogenous processing and presentation on major histocompatibility complex (MHC) molecules.

213 ones and was largely restricted by classical major histocompatibility complex (MHC) molecules.

214 AnthOligo was tested by capturing the Major Histocompatibility Complex (MHC) of a random sampl

215 he cellular form of the TRA and the class of major histocompatibility complex (MHC) on which antigen

216 on with the proteins of class I and class II major histocompatibility complex (MHC) pathways.

217 ttributable to either a TCR focus on exposed major histocompatibility complex (MHC) polymorphisms or

218 nsion that was dependent on the nonclassical major histocompatibility complex (MHC) protein CD1d, whi

219 immune response process is regulated by the major histocompatibility complex (MHC) protein which is

220 ed binding strengths to class-I and class-II major histocompatibility complex (MHC) proteins for 284

221 dies targeting human leukocyte antigen (HLA)/major histocompatibility complex (MHC) proteins limit su

222 e processed to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T cel

223 ecognize short peptide antigens presented on major histocompatibility complex (MHC) proteins.

224 The mammalian Major Histocompatibility Complex (MHC) region contains s

225 Multiple single variants within the major histocompatibility complex (MHC) region were obser

226 oci, with the strongest association from the major histocompatibility complex (MHC) region.

227 ant associations, in the IL28B/IFNL4 and the major histocompatibility complex (MHC) regions, with spo

228 Major histocompatibility complex (MHC) restriction is a

229 Major histocompatibility complex (MHC) restriction is a

230 ocus on the recovery of haplotype diversity, major histocompatibility complex (MHC) variants, satelli

231 (CD8 Treg) that recognize the Qa-1 class Ib major histocompatibility complex (MHC), a mouse homolog

232 d immunocompetence via heterozygosity at the major histocompatibility complex (MHC), a widely-used ge

233 tracellular complex comprising a peptide and major histocompatibility complex (MHC), and induce intra

234 The interaction between the class I major histocompatibility complex (MHC), the peptide pres

235 and recipients, most prominently within the major histocompatibility complex (MHC), which encodes hu

236 y we tested whether genetic variation in the major histocompatibility complex (MHC), which is associa

237 We assessed the evidence for major histocompatibility complex (MHC)-based mate prefer

238 is attributed to an absence of cell surface major histocompatibility complex (MHC)-I molecule expres

239 on free peptides or on those bound to their major histocompatibility complex (MHC)-I-presenting mole

240 We now show that major histocompatibility complex (MHC)-II and its master

241 Here we show the efficacy of major histocompatibility complex (MHC)-matched allogenei

242 se (GVHD) largely has been extrapolated from major histocompatibility complex (MHC)-matched murine sk

243 Using major histocompatibility complex (MHC)-mismatched and MH

244 In a full major histocompatibility complex (MHC)-mismatched, multi

245 cularly the third CDRs (CDR3s) interact with major histocompatibility complex (MHC)-presented epitope

246 Major histocompatibility complex (MHC)-related 1-restric

247 o generate diverse T cell subsets, including major histocompatibility complex (MHC)-restricted alphab

248 D) due to human T-cell recognition of murine major histocompatibility complex (MHC).

249 f hard to assemble gene clusters such as the major histocompatibility complex (MHC).

250 stinct from interactions between the TCR and major histocompatibility complex (MHC).

251 imal models, have become synonymous with the major histocompatibility complex (MHC).

252 iploid assembly is particularly useful - the Major Histocompatibility Complex (MHC).

253 recognition of antigens presented by class I major histocompatibility complex (MHC-I) proteins on tum

254 d production of recombinant patient-specific major histocompatibility complexes (MHC) loaded with the

255 Peptides bound to class I major histocompatibility complexes (MHC) play a critical

256 ing antigenic peptides presented by class II major histocompatibility complexes (MHC-II).

257 Mrc1, Retnla, and H2-a/e (encoding class II major histocompatibility complex [MHC] proteins) and man

258 UC-MSC) that present low antigenicity (i.e., major histocompatibility complex, MHC).

259 The major-histocompatibility-complex-(MHC)-class-I-related m

260 Peptide binding to major histocompatibility complexes (MHCs) is a central c

261 ional modeling of peptide display by class I major histocompatibility complexes (MHCs) is essential f

262 ablished skin transplant model with a single major histocompatibility complex mismatch, we compared t

263 ffect of Notch-1 receptor inhibition in full major histocompatibility complex-mismatch murine cardiac

264 underwent nonmyeloablative conditioning and major histocompatibility complex mismatched BMT with or

265 Using multimers of peptide major histocompatibility complex molecules (pMHC) and of

266 aVbeta module to recognize peptides bound to major histocompatibility complex molecules (pMHCs) in "v

267 nize the same antigenic peptide presented on major histocompatibility complex molecules but experienc

268 Ablation of endothelial cell class II major histocompatibility complex molecules by small inte

269 t recognize peptide antigens associated with major histocompatibility complex molecules expressed on

270 olerant and restricted to the recognition of major histocompatibility complex molecules presenting pe

271 as processors of antigen for presentation by major histocompatibility complex molecules, recent findi

272 ed linked SNPs in distinct blocks within the major histocompatibility complex on 6p21.

273 and upregulation of class I molecules of the major histocompatibility complex on tumour cells.

274 T-cell receptor (TCR) with a peptide-loaded major histocompatibility complex (p/MHC) leads to T-cell

275 unological tolerance by down-regulating both major histocompatibility complex pathways (MHC I and II)

276 is a fundamental metric of diversity at the major histocompatibility complex-peptide complex, which

277 thin which T cell receptor (TCR) and peptide major histocompatibility complex (pMHC) interact.

278 The natural peptide-major histocompatibility complex (pMHC) ligand for T cel

279 This interaction of pre-TCR with peptide-major histocompatibility complex (pMHC) molecules has re

280 ll receptor (TCR) binding to agonist peptide major histocompatibility complex (pMHC) triggers signali

281 f TCR sequences using a panel of peptide and major histocompatibility complex (pMHC)-tetramer-sorted

282 ted with autoimmune disease-relevant peptide-major histocompatibility complexes (pMHC) blunted autoim

283 are presented as processed peptides bound to major histocompatibility complexes (pMHC).

284 In searching for peptide-loaded major histocompatibility complexes (pMHCs), they must so

285 to functionally engage with multiple peptide-major histocompatibility complexes (pMHCs), we examined

286 itopes through interactions with peptide and major histocompatibility complexes (pMHCs).

287 -domain antibody specific for human class II major histocompatibility complex products and used it to

288 ope with the extremely polymorphic nature of major histocompatibility complex products within the spe

289 (HLA)-DQ2.5 (DQA1*05/DQB1*02) is a class-II major histocompatibility complex protein associated with

290 ct with foreign antigens bound to alleles of major histocompatibility complex proteins (MHC) that the

291 agonist peptides are presented to the TCR by major histocompatibility complex proteins expressed by a

292 system by trimming peptides for loading onto major histocompatibility complex proteins.

293 TNF signaling, psoriasis pathology, and the major histocompatibility complex region.

294 To perform detailed fine-mapping of the major-histocompatibility-complex region, we conducted ne

295 ognize antigens presented on non-polymorphic major histocompatibility complex-related 1 (MR1) molecul

296 athogenic SIV challenge virus, non-canonical major histocompatibility complex restriction, and absent

297 Ever since the discovery of the major histocompatibility complex, scientific and clinica

298 utable to infiltration of activated class II major histocompatibility complex(+) T cells.

299 her factors aside from intrinsic TCR-peptide-major histocompatibility complex (TCR-peptide-MHC) react

300 Register, three in the Dunedin study) in the major histocompatibility complex, which were associated